Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: A systematic review

Anti-Cancer Drugs

Volumn 21, Issue 5, 2010, Pages 487-493

  Yip, Adrian Yun San ^a,b   Tse, Lap Ah ^a   Ong, Eleanor Yuen Yuen ^b   Chow, Louis Wing Cheong ^b,c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Advanced breast cancer; Lapatinib; Meta analysis; Metastatic breast cancer; Systematic review

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; LETROZOLE; PACLITAXEL; TRASTUZUMAB;

ADVANCED CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COCHRANE LIBRARY; EMBASE; GENE OVEREXPRESSION; HUMAN; MEDLINE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 77951298743     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283388eaf     Document Type: Review

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
3. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002 cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5, version 2.0. Lyon: IARC Press; 2004.
4. Parkin DM, Fernández LM. Use of statistics to assess the global burden of breast cancer. Breast J 2006; 12:S70-S80.
5. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
6. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7:96.
7. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J ClinOncol 2001; 19:2722-2730.
8. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1:85-94.
9. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, et al. Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21:6255-6263.
10. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66:1630-1639.
11. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008; 26:2999-3005.
12. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [document on the Internet]. The Cochrane Collaboration; 2008 [updated September 2008; cited 31 December 2008]. Available from: http://www.cochrane-handbook.org
13. Review Manager (RevMan) [computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration; 2008.
14. Guarneri V, Frassoldati A, Piacentini F, Jovic G, Giovannelli S, Oliva C, et al. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial). Clin Breast Cancer 2008; 8:192-194.
15. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112:533-543.
16. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008; 26:5544-5552.
17. Johnston S, Pegram M, Press M, Pippen J, Pivot X, Gomez H, et al. First-Line therapy with lapatinib combined with letrozole versus letrozole alone for postmenopausal hormone receptor positive MBC: First results from the phase III double-blind EGF30008 trial [webcast presentations on the Internet]. San Antonio Breast Cancer Symposium; 2008 [updated December 2008; cited 31 March 2008]. Available from: http:// sabcs08.m2usa.com/sabcsol.html
18. GlaxoSmithKline. Protocol Summary for EGF30008 [webpage on the Internet]. GSK Clinical Trial Register; 2008 [updated May 2009; cited 19 May 2009]. Available from: http://www.gsk-clinicalstudyregister.com/ protocol- detail.jsp?protocolId=EGF30008&studyId=20703&compound=Lapatinib
19. Slamon DJ, Clark GM,Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182.
20. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve- Söderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10:1049-1056.
21. Volpi A, Nanni O, De Paola F, Granato AM, Mangia A, Monti F, et al. HER-2 expression and cell proliferation: prognostic markers in patients with nodenegative breast cancer. J Clin Oncol 2003; 21:2708-2712.
22. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002; 20:3095-3105.
23. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-726.
24. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-2648.
25. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3:269-280.
26. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-137.
27. McArthur H. An overview of HER-targeted therapy with lapatinib in breast cancer. Adv Ther 2009; 26:263-271.
28. Bruzzi P, Del Mastro L, Sormani MP, Bastholt L, Danova M, Focan C, et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol 2005; 23: 5117-5125.
29. Zhou X, Cella D, Cameron D, Amonkar MM, Segreti A, Stein S, et al. Lapatinib plus capecitabine versus capecitabine alone for HER2 + (ErbB2 +) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat 2009; 117:577-589.
30. Schneider JW, Chang AY, Rocco TP. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. Semin Oncol 2001; 28:18-26.
31. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005; 23:2900-2902.
32. Perez EA. Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin Breast Cancer 2008; 8:S114-S120.
33. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008; 83:679-686.
34. Rosenthal R, Sutton AJ, Bornstein M, editors. Publication bias in meta-analysis: Prevention, assessment, and adjustments. Chichester, UK: Wiley; 2005.
35. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127:820-826.
36. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005; 15:865s-870s. (Pubitemid 40111098)
37. Lin NU, Dié ras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15:1452-1459.
38. Glück S, Castrellon A. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases. Am J Ther 2009; 16:585-590.
39. Tomasello G, de Azambuja E, Dinh P, Snoj N, Piccart-Gebhart M. Jumping higher: is it still possible? The ALTTO trial challenge. Expert Rev Anticancer Ther 2008; 8:1883-1890.
40. De Azambuja E, Cardoso F, Meirsman L, Straehle C, Dolci S, Vantongelen K, et al. The new generation of breast cancer clinical trials: the right drug for the right target [in French]. Bull Cancer 2008; 95:352-357.